Corcept Therapeutics (CORT) Net Cash Flow (2010 - 2026)
Corcept Therapeutics (CORT) posted Net Cash Flow of $2.3 million for Q2 2026, up 119.74% sequentially from -$11.5 million in Q1 2026, and down 80.3% YoY from $11.5 million in Q2 2025.
Corcept Therapeutics (CORT) Net Cash Flow (2010 - 2026) Analysis & Trends
Corcept Therapeutics has reported Net Cash Flow for 17 years, with the latest figure at $2.3 million in Q2 2026.
- Quarterly Net Cash Flow fell 80.3% year-over-year to $2.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $8.9 million (up 132.45% YoY) and the FY2025 annual result came in at -$8.6 million, down 12.46% from the prior year.
- Net Cash Flow climbed to $2.3 million in Q2 2026 per CORT's latest filing, from -$11.5 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $233.6 million in Q1 2023 and troughed at -$127.6 million in Q2 2023.
- A 5-year average of $1.8 million and a median of -$1.2 million in 2025 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Net Cash Flow soared 2107.68% in 2022, then sank 506.64% in 2023.
- Over 5 years, Net Cash Flow stood at $16.1 million in 2022, then soared by 45.42% to $23.4 million in 2023, then slumped by 137.9% to -$8.9 million in 2024, then soared by 47.99% to -$4.6 million in 2025, then jumped by 149.1% to $2.3 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $2.3 million, -$11.5 million, and -$4.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Corcept Therapeutics | 12.37 Bn | 12.07 Bn | 252.09 Mn | 2.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.26 Mn |
| Jun 30, 2026 | 2.26 Mn |
| Mar 31, 2026 | -11.47 Mn |
| Mar 31, 2026 | -11.47 Mn |
| Dec 31, 2025 | -4.61 Mn |
| Dec 31, 2025 | -4.61 Mn |
| Sep 30, 2025 | 22.71 Mn |
| Sep 30, 2025 | 22.71 Mn |
| Jun 30, 2025 | 11.49 Mn |
| Jun 30, 2025 | 11.49 Mn |
| Mar 31, 2025 | -38.20 Mn |
| Mar 31, 2025 | -38.20 Mn |
| Dec 31, 2024 | -8.87 Mn |
| Dec 31, 2024 | -8.87 Mn |
| Sep 30, 2024 | 8.17 Mn |
| Sep 30, 2024 | 8.17 Mn |
| Jun 30, 2024 | -21.16 Mn |
| Jun 30, 2024 | -21.16 Mn |
| Mar 31, 2024 | 14.20 Mn |
| Mar 31, 2024 | 14.20 Mn |